# A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer

> **NCT04557384** · PHASE1 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 3 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** Ramucirumab

## Key facts

- **NCT ID:** NCT04557384
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-23
- **Primary completion:** 2021-05-25
- **Final completion:** 2021-05-25
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Study terminated due to inadequate PK profile associated with the subcutaneous formulation.
- **Last updated:** 2023-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04557384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04557384, "A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04557384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*